Therapy News and Research

RSS

Biogen Idec, Swedish Orphan Biovitrum present results from rFIXFc Phase 1/2a study in hemophilia B

Biogen Idec and Swedish Orphan Biovitrum AB today announced results from a Phase 1/2a open-label, dose-escalation, safety and pharmacokinetic study of the companies' long-lasting, fully-recombinant factor IX Fc fusion protein (rFIXFc) in hemophilia B patients. The data, which were presented at the World Federation of Hemophilia Congress in Buenos Aires, Argentina, on July 11, 2010, showed that rFIXFc was well tolerated and demonstrated an approximately three-fold increase in half-life compared to historical data for existing therapies.

12 Jul 2010

Reducing chronic pain, dry mouth could improve quality of life in head and neck cancer patients: Study

Head and neck cancer patients who reported poor sleep quality one year after diagnosis had more symptoms of chronic pain and complaints of dry mouth related to radiation treatments, according to a recent study from the University of Michigan Comprehensive Cancer Center.

12 Jul 2010

Report shows experimental trials have higher risk for bias

A Johns Hopkins review of nearly 150 randomized controlled trials on children - all published in well-regarded medical journals - reveals that 40 to 60 percent of the studies either failed to take steps to minimize risk for bias or to at least properly describe those measures.

12 Jul 2010

Deaths from heroin overdoses in Chicago's Cook County fall 16%: Study

A new study by Roosevelt University's Illinois Consortium on Drug Policy shows deaths from heroin overdoses in Chicago's Cook County fell 16 percent during the last decade, but the Chicago metropolitan region still ranks among the worst in the nation for heroin use. Kimberly Dennis, M.D., eating disorder specialist at Chicago's Timberline Knolls Residential Treatment Center, sees the use of heroin regularly from women and girls she treats and knows the importance of awareness and seeking help to overcome this addiction.

12 Jul 2010

Alliance HealthCare Services acquires certain radiation therapy assets from Arkansas Cancer Center

Alliance HealthCare Services, Inc.), a leading national provider of outpatient diagnostic imaging and radiation therapy services, announced the acquisition of certain radiation therapy assets from Arkansas Cancer Center, P.A. The purchase price is expected to total approximately $9 million in cash and assumed indebtedness.

12 Jul 2010

Study results show no improvement in overall survival for combination of gemcitabine and Amplimexon

AmpliMed Corporation, a cancer therapeutics company, today announced results from AMP-019, a randomized double-blind, placebo-controlled Phase II screening trial designed to determine if a Phase III trial was warranted for the combination of gemcitabine (Gemzar, Eli Lilly) plus Amplimexon (AmpliMed Corporation) in patients with advanced pancreatic ductal adenocarcinoma of the pancreas.

12 Jul 2010

Hip and knee specialist indicates five primary reasons why knee implant fails

While most knee replacements will function well for years, patients should be aware of the signs of failure—including increased pain or decreased function—that may require a corrective procedure known as revision total knee replacement, if necessary.

12 Jul 2010

Discovery of antibodies that kill more than 90% of HIV viruses gives new hope for vaccine

"An effective vaccine against the AIDS virus may have moved one step closer to reality, researchers said Thursday," the Los Angeles Times reports. "Federal researchers have identified a pair of naturally occurring antibodies that are able to kill more than 90% of all strains of the AIDS virus, a finding they say could lead to the development of new treatments for HIV infections and to the production of the first successful vaccine against the virus" (Maugh, 7/9).

12 Jul 2010

Mesoblast schedules formal meeting with FDA to discuss proposed Phase 3 clinical trial program

Australian regenerative medicine company, Mesoblast Limited, today announced that based on positive results from its bone marrow transplant clinical trial conducted at the University of Texas MD Anderson Cancer Center, a formal meeting has been scheduled with the United States Food and Drug Administration to discuss a proposed Phase 3 clinical trial program.

12 Jul 2010

Researchers demonstrate that MSNs can effectively suppress tumors in mice

The application of nanotechnology in the field of drug delivery has attracted much attention in recent years. In cancer research, nanotechnology holds great promise for the development of targeted, localized delivery of anticancer drugs, in which only cancer cells are affected.

12 Jul 2010

CPhA welcomes announcement of agreement to lower generic drug prices

The Canadian Pharmacists Association today welcomed the announcement of an agreement reached between the Government of British Columbia, the British Columbia Pharmacy Association, and the Canadian Association of Chain Drug Stores to lower generic drug prices and invest in expanded pharmacy services.

12 Jul 2010

Phase III study results of imiquimod creams for treatment of EGW presented at HPV Conference

Results from a Phase III program evaluating imiquimod 3.75% and 2.5% creams for the treatment of EGW, applied once daily for up to 8 weeks, demonstrated that both were well-tolerated and more efficacious than placebo, according to data presented at the annual Human Papillomavirus Conference in Montreal, July 3 - 8. Investigators found that efficacy was greatest for imiquimod 3.75% with an enhanced safety profile.

9 Jul 2010

MJFF awards $1.1M to six different projects for validating potential therapeutic targets for PD

The Michael J. Fox Foundation for Parkinson's Research today announced $1.1 million in total funding to six different projects aimed at validating potential therapeutic targets for Parkinson's disease.

9 Jul 2010

Pfizer to present results of hemophilia studies at WFH 2010 Congress

Pfizer Inc, the world's leading biopharmaceutical company, today announced that the results of a number of hemophilia studies will be presented at the World Federation of Hemophilia 2010 Congress taking place July 10-14, 2010, in Buenos Aires, Argentina. Key research includes a pre-clinical evaluation of recombinant factor Xa as a potential new approach to restoring hemostasis, as well as a study assessing the potential for an engineered recombinant factor VIIa molecule to improve therapeutic outcomes in mouse models of hemophilia.

9 Jul 2010

Semuloparin reduces incidence of VTE in orthopedic surgery patients, study finds

An ultra-low-molecular-weight heparin called semuloparin has been found to reduce the incidence of venous thromboembolism in orthopedic surgery patients in a large clinical program being lead by a steering committee chaired by McMaster University professor Dr. Alexander Turpie.

9 Jul 2010

AHF: 15 Zambian health care professionals to train HIV Medics

Graduation ceremonies will be held Saturday, July 10th in Lukasa for 15 Zambian health care professionals from several districts throughout the country who have completed an educational training program administered by AIDS Healthcare Foundation. This will enable the graduates to train classes of HIV Medics to work in the country's growing fight against HIV/AIDS.

9 Jul 2010

Oklahoma City ProCure Proton Therapy Center celebrates first-year anniversary

Past and present patients, families, friends, staff and physicians of ProCure Proton Therapy Center in Oklahoma City commemorated a year of achievements at a celebratory luncheon Thursday at the center in northwest Oklahoma City.

9 Jul 2010

New method enhances delivery of DNA payloads into cells

Chang Lu and his chemical engineering research group at Virginia Tech have discovered how to "greatly enhance" the delivery of DNA payloads into cells. The description of their work will be featured on the cover of Lab on a Chip (issue 16), the premier journal for researchers in microfluidics.

9 Jul 2010

Promising study may lead to potential new therapeutics for women facing triple-negative breast cancer

Using a small molecule decoy, investigators funded by the Samuel Waxman Cancer Research Foundation have managed to block protein interactions and induce epigenetic reprogramming in human and mouse breast cancer cells, essentially changing the gene expression of breast cancer cells to behave in a more normal manner.

9 Jul 2010

Skandion Clinic selects IBA for installation of particle therapy facility

IBA (Ion Beam Applications S.A.) announced that Skandion Clinic, the clinical centre for proton therapy in Sweden, has selected IBA for the installation of a particle therapy facility. This new center will be managed by a consortium of seven Swedish counties, representing eight university hospitals.

9 Jul 2010

Therapy News and Research

Biogen Idec, Swedish Orphan Biovitrum present results from rFIXFc Phase 1/2a study in hemophilia B

Reducing chronic pain, dry mouth could improve quality of life in head and neck cancer patients: Study

Report shows experimental trials have higher risk for bias

Deaths from heroin overdoses in Chicago's Cook County fall 16%: Study

Alliance HealthCare Services acquires certain radiation therapy assets from Arkansas Cancer Center

Study results show no improvement in overall survival for combination of gemcitabine and Amplimexon

Hip and knee specialist indicates five primary reasons why knee implant fails

Discovery of antibodies that kill more than 90% of HIV viruses gives new hope for vaccine

Mesoblast schedules formal meeting with FDA to discuss proposed Phase 3 clinical trial program

Researchers demonstrate that MSNs can effectively suppress tumors in mice

CPhA welcomes announcement of agreement to lower generic drug prices

Phase III study results of imiquimod creams for treatment of EGW presented at HPV Conference

MJFF awards $1.1M to six different projects for validating potential therapeutic targets for PD

Pfizer to present results of hemophilia studies at WFH 2010 Congress

Semuloparin reduces incidence of VTE in orthopedic surgery patients, study finds

AHF: 15 Zambian health care professionals to train HIV Medics

Oklahoma City ProCure Proton Therapy Center celebrates first-year anniversary

New method enhances delivery of DNA payloads into cells

Promising study may lead to potential new therapeutics for women facing triple-negative breast cancer

Skandion Clinic selects IBA for installation of particle therapy facility

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News